Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO ...

NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Regeneron Pharmaceuticals REGN Get Free Report has outperformed the market over the past 15 years by 12.37% on an annualized ...

This was the stock's second consecutive day of losses.

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...

The stock's fall snapped a three-day winning streak.